Figure 1.
Course of LDL cholesterol under bulevirtide treatment in individual participants. Primary endpoint was change in LDL cholesterol after 12 weeks of treatment (Visit W13D1, highlighted): Participants with decrease of LDL cholesterol > 19.6 mg/dL in blue (“responder”); participants with no decrease and decrease < 19.6 mg/dL of LDL cholesterol in red (“non-responder”). Green: Hodges–Lehmann estimator with 95% confidence interval.